 UniQure NV NASDAQ: QURE announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 12 trial of AMT-130 for Huntingtons disease. AMT-130 was generally well tolerated at the lower dose of 6x1012 vector genomes vg. 